[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"multiomics\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:multiomics":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,95,118],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100629955","molecular-insights-into-post-cardiac-arrest-brain-injury-via-csf-multi-omics-100629955",false,"NCT07481396","Molecular Insights Into Post-Cardiac Arrest Brain Injury Via CSF Multi-Omics","Identification of Novel Molecular Pathophysiological Mechanisms of Secondary Brain Injury in Post-cardiac Arrest Syndrome Patients Using Cerebrospinal Fluid Multi-omics Analysis","PCABI-OMICS","Inclusion Criteria:\n\n* Patients receiving post-resuscitation care after out-of-hospital cardiac arrest for secondary brain injury treatment.\n* Patients without contraindications for lumbar puncture catheter insertion for cerebrospinal fluid (CSF) collection. This includes the absence of:\n* Uncontrolled diabetes.Coagulation disorders.\n* Thrombocytopenia (platelet count $\\\u003C 100,000).\n* A history of cirrhosis diagnosis.\n* Current receipt of low molecular weight heparin.\n* Current use of platelet inhibitors.\n* A history of posterior spinal fusion that may interfere with catheter insertion.\n* Local skin infection or rash at the puncture site.\n* Signs of systemic infection or sepsis.\n* A history of lumbar puncture within the past 6 hours.\n\nExclusion Criteria:\n\n* Cerebral Edema: Patients with evidence of cerebral edema on a brain computed tomography (CT) scan performed immediately after spontaneous circulation recovery.\n* Patients who underwent extracorporeal membrane oxygenation (ECMO).\n* Patients who could not maintain integrated therapy for more than 24 hours after cardiac arrest.\n* Patients with a history of acute or chronic brain disease.","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","3 Months","OBSERVATIONAL","The goal of this study is to uncover the molecular mechanisms responsible for secondary brain injury in patients with post-cardiac arrest syndrome by analyzing cerebrospinal fluid (CSF) using multi-omics techniques.\n\nThe main question this study aims to answer is:\n\nWhich genome-, transcriptome-, proteome-, and metabolome-level changes in CSF are associated with secondary brain injury after cardiac arrest?\n\nTo address this question, CSF samples collected from post-cardiac arrest patients will undergo multi-omics analyses. Identified molecular pathways will be used to screen existing drug databases and generate new therapeutic candidates through computational modeling and compound synthesis. These findings will provide the scientific foundation needed to design and implement future preclinical experiments using cardiac arrest animal models.",[26,27,28,29],"Cardiac Arrest (CA)","Cerebrospinal Fluid","Multiomics","Hypoxic-Ischemic Brain Injury","RECRUITING","2026-03-16",{"date":33,"type":34},"2026-03-18","ACTUAL",{"date":36,"type":34},"2025-12-01",{"date":38,"type":21},"2028-02-28",{"name":40,"class":41},"Chungnam National University Hospital","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":68,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":4},"100628100","probiotic-research-open-label-functional-intervention-and-longitudinal-evaluation-in-healthy-adults-100628100","NCT07457242","Probiotic Research: Open-label Functional Intervention and Longitudinal Evaluation in Healthy Adults","PROFILE","Inclusion Criteria:\n\n* Aged 18 years or older at the time of providing informed consent.\n* In generally good health, with no known medical conditions that could interfere with the aims of the study or participant safety, as judged by self-report and screening questionnaire.\n* No history of significant psychiatric or neurological illness\n* Ability to complete study specific tasks, including:\n* Daily oral intake of a probiotic capsule\n* Self-collection of stool samples\n* Completion of online questionnaires and simple cognitive tasks\n* Able to read, understand, and communicate in English, in order to give informed consent and follow study instructions.\n* Access to the internet and a suitable device (e.g., smartphone, tablet, or computer) for completing online aspects of the study.\n\nExclusion Criteria:\n\n* Participants will be excluded from the study if any of the following criteria apply:\n* Use of any systemic antibiotic or systemic immunosuppressive medication within the past 8 weeks, including but not limited to:\n* β-lactam antibiotics, macrolides, tetracyclines, fluoroquinolones, aminoglycosides, glycopeptides, sulfonamides, antimycobacterial agents, systemic antifungals or antivirals\n* Use of any systemic immunosuppressants within the past 16 weeks, including, but not limited to:\n* Systemic corticosteroids, conventional immunosuppressants, biologic immunomodulators, targeted synthetic immunosuppressants, cytotoxic chemotherapy, or transplant-related immunosuppression.\n* A longer exclusion window is applied for systemic immunosuppressive therapies due to their prolonged and potentially lasting effects on immune function and gut microbial composition compared with systemic antibiotics.\n* Participants who commence systemic antibiotics or immunosuppressive therapy after enrolment will not be withdrawn from safety monitoring but will stop the supplement and will not continue the intervention phase of the study. With participant consent, data collected may still be used.\n* Major gastrointestinal disease or surgery:\n* Any history of significant gastrointestinal disease or surgery that may alter gut microbiome composition, immune function, or nutrient absorption, including but not limited to inflammatory bowel disease (Crohn's disease, ulcerative colitis, indeterminate colitis); coeliac disease or other chronic malabsorptive disorders; chronic liver, biliary, or pancreatic disease; moderate-to-severe or unstable irritable bowel syndrome; gastrointestinal malignancy; chronic gastrointestinal motility disorders; recurrent Clostridioides difficile infection; or any major gastrointestinal surgery such as bowel resection, bariatric surgery, colectomy, ileostomy or colostomy. Prior appendectomy or cholecystectomy alone is not exclusionary.\n* Current pregnancy or development of pregnancy, breastfeeding\n* Known allergy to probiotic or compounding ingredients:\n* Vitamin D3\n* Isomaltooligosaccharide\n* Yeast extract",true,{"count":52,"type":21},180,"INTERVENTIONAL",[55],"NA","This study is a pre-post, open-label cohort study designed to investigate how a food-grade probiotic supplement affects biological measurements and wellbeing in healthy adults. Participants will take one capsule daily for either 1 month or 6 months.\n\nDuring the study, participants will complete online cognitive tasks and provide blood and stool samples collected during home visits by trained staff. The samples will be analysed to explore changes in gut bacteria and other biological markers.\n\nThis study aims to understand whether the supplement is well tolerated and whether measurable biological changes occur. The study does not involve any experimental drugs or invasive procedures beyond blood sampling and stool collection, and participants will not be asked to change any current prescribed medications or treatments; with eligibility exclusions applying for recent antibiotics or immunosuppressants. The supplement is being studied for research purposes only and is not intended to diagnose, treat, or prevent disease. Participants will be invited to participate in a follow-up visit to assess long-term effects.",[58,28,59,60,61,62,63,64,65,66,67],"Cognition","Microbiome Analysis","Metabolome","Proteome","Metagenome","Probiotics Supplement","Gut-brain Axis","Pilot Study","Adult","Sleep",[69,70,71,72,73,74,75,76,77,78,79,80,81,82,83],"Probiotics","Dietary Supplements","Microbiome","Multi-omics","Metabolomics","Proteomics","Mitochondrial Function","Cellular Metabolism","Short-Chain Fatty Acids","Bioinformatics","Healthy volunteers","Pilot study","feasibility study","cognitive function","mental health","NOT_YET_RECRUITING","2026-03-03",{"date":87,"type":34},"2026-03-09",{"date":89,"type":21},"2026-07-01",{"date":91,"type":21},"2027-07-01",{"name":93,"class":94},"OneCarbon","INDUSTRY",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":103,"targetDuration":105,"studyType":23,"phases":4,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":42},"100504760","molecularly-aided-stratification-for-tumor-eradication-research-100504760","NCT05852522","Molecularly Aided Stratification for Tumor Eradication Research","NCT MASTER Plattform Molecularly Aided Stratification for Tumor Eradication Research","NCT-MASTER","Inclusion Criteria:\n\nRare cancer (Incidence \\\u003C6\u002F100,000 persons\u002Fyear) or Rare subtype of a more common entity (case-by-case decision; example: pancreatic ductal adenocarcinoma without KRAS mutation)\n\nMetastatic and\u002For locally advanced cancer with no curative therapy option and indication for systemic therapy\n\nExclusion Criteria:\n\nSevere neurological or psychiatric disorder interfering with the ability to give oral and written informed consent",{"count":104,"type":21},10000,"10 Years","NCT\u002FDKFZ\u002FDKTK MASTER is a prospective, continuously recruiting, multicenter observational study for biology-guided stratification of adults with rare cancers, including rare subtypes of common entities, using comprehensive molecular profiling, and clinical decision-making in a multidisciplinary molecular tumor board.",[108,28],"Rare Cancers","2025-02-28",{"date":111,"type":34},"2025-03-04",{"date":113,"type":34},"2018-11-11",{"date":115,"type":21},"2029-10",{"name":117,"class":41},"German Cancer Research Center",{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":125,"minAge":4,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":128,"conditions":129,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":5},"100538087","ai-assisted-system-for-accurate-diagnosis-and-prognosis-of-breast-phyllodes-tumors-100538087","NCT06286267","AI-Assisted System for Accurate Diagnosis and Prognosis of Breast Phyllodes Tumors","Development of an Artificial Intelligence-Based System for Precise Diagnosis and Prognosis of Breast Phyllodes Tumors","Inclusion Criteria:\n\n* Patients diagnosed with a phyllodes tumor of the breast\n\nExclusion Criteria:\n\n* Blurred images, imaging artifacts","FEMALE",{"count":127,"type":21},4000,"Breast phyllodes tumor (PT) is a rare fibroepithelial tumor, accounting for 1% to 3% of all breast tumors, categorized by the WHO into benign, borderline, and malignant, based on histopathology features such as tumor border, stromal cellularity, stromal atypia, mitotic activity and stromal overgrowth. Malignant PTs account for 18%-25%, with high local recurrence (up to 65%) and distant metastasis rates (16%-25%). Benign PT could progress to malignancy after multiple recurrences. Therefore, Early, accurate diagnosis and identification of therapeutic targets are crucial for improving outcomes and survival rates.\n\nIn recent years, there has been growing interest in the application of artificial intelligence (AI) in medical diagnostics. AI can integrate clinical information, histopathological images, and multi-omics data to assist in pathological and clinical diagnosis, prognosis prediction, and molecular profiling.AI has shown promising results in various areas, including the diagnosis of different cancers such as colorectal cancer, breast cancer, and prostate cancer. However, PT differs from breast cancer in diagnosis and treatment approach. Therefore, establishing an AI-based system for the precise diagnosis and prognosis assessment of PT is crucial for personalized medicine.\n\nThe research team, led by Dr. Nie Yan, is one of the few in Guangdong Province and even nationally, specializing in PT research. Their team has been conducting research on the malignant progression, metastasis mechanisms, and molecular markers for PT. The team has identified key mechanisms, such as fibroblast-to-myofibroblast differentiation, and the role of tumor-associated macrophages in promoting this differentiation. They have also identified molecular markers, including miR-21, α-SMA, CCL18, and CCL5, which are more accurate in predicting tumor recurrence risk compared to traditional histopathological grading.\n\nThe project has collected high-quality data from nearly a thousand breast PT patients, including imaging, histopathology, and survival data, and has performed transcriptome gene sequencing on tissue samples. They aim to build a comprehensive multi-omics database for breast PT and create an AI-based model for early diagnosis and prognosis prediction. This research has the potential to improve the diagnosis and treatment of breast PT, address the disparities in breast PT care across different regions in China, and contribute to the development of new therapeutic targets.",[130,131,28,132,133],"Phyllodes Breast Tumor","Artificial Intelligence","Prognostic Cancer Model","Diagnosis","2024-02-22",{"date":136,"type":34},"2024-02-29",{"date":138,"type":34},"2023-03-01",{"date":140,"type":21},"2027-12-31",{"name":142,"class":41},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University"]